
USA - NASDAQ:EPZM - US29428V1044 - Common Stock
ChartMill assigns a Buy % Consensus number of 78% to EPZM. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-06-28 | Cowen & Co. | Downgrade | Outperform -> Market Perform |
| 2022-06-27 | Wedbush | Downgrade | Outperform -> Neutral |
| 2022-06-03 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-12 | HC Wainwright & Co. | Maintains | Buy |
| 2022-03-02 | HC Wainwright & Co. | Maintains | Buy |
| 2021-08-10 | Morgan Stanley | Downgrade | Equal-Weight -> Underweight |
| 2021-08-10 | HC Wainwright & Co. | Maintains | Buy |
| 2021-05-07 | SVB Leerink | Upgrade | Market Perform -> Outperform |
| 2021-05-07 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-04-19 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-03-31 | Credit Suisse | Initiate | Outperform |
| 2021-02-25 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
9 analysts have analysed EPZM and the average price target is 3.04 USD. This implies a price increase of 107% is expected in the next year compared to the current price of 1.47.
The consensus rating for EPIZYME INC (EPZM) is 77.7778 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering EPIZYME INC (EPZM) is 9.